Wall Street consensus ratings for Exact Sciences Corporation (NASDAQ: EXAS) generally lean toward a Buy, supported by strong adoption of its non-invasive cancer diagnostics like Cologuard. What are your primary financial return goals and portfolio risk parameters? Professional financial guidance is recommended before executing trades.